Taken together, these results indicated that SETD5 may be an oncogenic factor; this finding is supported by the oncogenic role of other SET domain protein family members [8, 10, 11], except SETD2, which was demonstrated to be a tumor suppressor in renal and breast carcinomas [12, 14–16, 29]. This evidence concerns the gene SETD5 and breast carcinoma.